Abstract
The pharmacological treatment of colorectal tumour leads to MultiDrug Resistance due to overexpression of several ABC transporters such as P-glycoprotein and some Multidrug associated Resistance Proteins (MRPs) that are able to efflux the chemotherapeutic agent out of the cell. A strategy to reverse MDR is the co-administration of antineoplastic agent with a P-glycoprotein inhibitor. These inhibitors are an useful tool for investigating, by PET, the expression and the activity of P-gp and MRPs that are overexpressed in chemoresistant colorectal tumor cells. In this review will be focused the aspect on P-gp and MRPs ligands employed as PET radiotracers considering their pharmacokinetic pharmacodynamic profile and their selectivity towards ABC transporters involved in chemoresistant cell of colorectal tumour.
Keywords: Colorectal, cancer, PET, P-glycoprotein, MultiDrug Resistance, 11-C radiotracers, Everted gut sac, neuroblastoma, epipodophyllotoxins, Nucleotide Binding domains (NBDs)
Current Drug Metabolism
Title: Clinical Pharmacokinetic and Metabolism of PET Radiotracers for Imaging P-glycoprotein in Chemoresistant Tumor of Colorectal Cancer
Volume: 12 Issue: 10
Author(s): Mariangela Cantore, Elena Capparelli, Francesco Berardi, Roberto Perrone and Nicola Antonio Colabufo
Affiliation:
Keywords: Colorectal, cancer, PET, P-glycoprotein, MultiDrug Resistance, 11-C radiotracers, Everted gut sac, neuroblastoma, epipodophyllotoxins, Nucleotide Binding domains (NBDs)
Abstract: The pharmacological treatment of colorectal tumour leads to MultiDrug Resistance due to overexpression of several ABC transporters such as P-glycoprotein and some Multidrug associated Resistance Proteins (MRPs) that are able to efflux the chemotherapeutic agent out of the cell. A strategy to reverse MDR is the co-administration of antineoplastic agent with a P-glycoprotein inhibitor. These inhibitors are an useful tool for investigating, by PET, the expression and the activity of P-gp and MRPs that are overexpressed in chemoresistant colorectal tumor cells. In this review will be focused the aspect on P-gp and MRPs ligands employed as PET radiotracers considering their pharmacokinetic pharmacodynamic profile and their selectivity towards ABC transporters involved in chemoresistant cell of colorectal tumour.
Export Options
About this article
Cite this article as:
Cantore Mariangela, Capparelli Elena, Berardi Francesco, Perrone Roberto and Antonio Colabufo Nicola, Clinical Pharmacokinetic and Metabolism of PET Radiotracers for Imaging P-glycoprotein in Chemoresistant Tumor of Colorectal Cancer, Current Drug Metabolism 2011; 12 (10) . https://dx.doi.org/10.2174/138920011798062292
DOI https://dx.doi.org/10.2174/138920011798062292 |
Print ISSN 1389-2002 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5453 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Topoisomerase I-DNA Complex Stability Induced by Camptothecins and Its Role in Drug Activity&#
Current Medicinal Chemistry - Anti-Cancer Agents Matrix Metalloproteinases and Colon Anastomosis Repair: A New Indication for Pharmacological Inhibition?
Mini-Reviews in Medicinal Chemistry Design Strategies, Structures and Molecular Interactions of Small Molecule Src Inhibitors
Anti-Cancer Agents in Medicinal Chemistry Advances of Phenoxazines: Synthesis, Reactivity and Their Medicinal Applications
Current Medicinal Chemistry Targeted Theranostics Against Solid Cancer Using Metal Bond Milk Protein and Aptamers
Current Topics in Medicinal Chemistry Mir-320b Inhibits Pancreatic Cancer Cell Proliferation by Targeting FOXM1
Current Pharmaceutical Biotechnology Phase 1 Clinical Experience Using Intravenous Administration of PV701, an Oncolytic Newcastle Disease Virus
Current Cancer Drug Targets ADAM Proteins- Therapeutic Potential in Cancer
Current Cancer Drug Targets Accelerated Cytotoxicity Mechanism Screening Using Drug Metabolising Enzyme Modulators
Current Drug Metabolism Natural Products as Promising Drug Candidates for the Treatment of Alzheimer’s Disease: Molecular Mechanism Aspect
Current Neuropharmacology The Role of Connexins in Carcinogenesis: Review of Current Knowledge
Current Signal Transduction Therapy Angiotensin-Converting Enzymes (ACE and ACE2) as Potential Targets for Malignant Epithelial Neoplasia: Review and Bioinformatics Analyses Focused in Oral Squamous Cell Carcinoma
Protein & Peptide Letters An Augmented Passive Immune Therapy to Treat Fulminant Bacterial Infections
Recent Patents on Anti-Infective Drug Discovery Angiotensin-(1-7): A Peptide Hormone with Anti-Cancer Activity
Current Medicinal Chemistry Identification of Multiple Subcellular Locations for Proteins in Budding Yeast
Current Bioinformatics Role of Flavonoids in Future Anticancer Therapy by Eliminating the Cancer Stem Cells
Current Stem Cell Research & Therapy MicroRNAs in Cancer: Small Molecules, Big Chances
Anti-Cancer Agents in Medicinal Chemistry Extracellular Signal-Regulated Kinases Modulate DNA Damage Response - A Contributing Factor to Using MEK Inhibitors in Cancer Therapy
Current Medicinal Chemistry New Generation of Oncolytic Herpes Virus
Current Cancer Therapy Reviews Cyclooxygenase-2 Biology
Current Pharmaceutical Design